| Literature DB >> 26933620 |
Dino Samartzis1, Christopher C Gillis2, Patrick Shih3, John E O'Toole2, Richard G Fessler2.
Abstract
Study Design Broad narrative review. Objectives Intramedullary spinal cord tumors (IMSCT) are uncommon lesions that can affect any age group or sex. However, numerous IMSCT exist and the clinical course of each tumor varies. The following article addresses the various management options and outcomes in patients with IMSCT. Methods An extensive review of the peer-reviewed literature was performed, addressing management options and clinical outcomes of patients with IMSCT. Results Early diagnosis and intervention are essential to obtain optimal functional outcome. Each IMSCT have specific imaging characteristics, which help in the clinical decision-making and prognostication. A comprehension of the tumor pathology and the clinical course associated with each tumor can allow for the proper surgical and nonsurgical management of these tumors, and reduce any associated morbidity and mortality. Recent advances in the operative management of such lesions have increased the success rate of tumor removal while minimizing iatrogenic-related trauma to the patient and, in tandem, improving patient outcomes. Conclusions Awareness and understanding of IMSCT is imperative to design proper management and obtain optimal patient outcomes. Meticulous operative technique and the use of surgical adjuncts are essential to accomplish proper tumor removal, diminish the risk of recurrence, and preserve neurologic function. Operative management of IMSCT should be individualized and based on tumor type, location, and dimensional extensions. To assist with preoperative and intraoperative decision-making, a general algorithm is provided.Entities:
Keywords: cord; intradural; intramedullary; outcomes; spinal; spine; surgery; tumors
Year: 2015 PMID: 26933620 PMCID: PMC4771497 DOI: 10.1055/s-0035-1550086
Source DB: PubMed Journal: Global Spine J ISSN: 2192-5682
Fig. 1(A) Intraoperative view of cervical intramedullary ependymoma with large extramedullary extension. Tumor also wrapped around spinal cord to occupy the ventral extramedullary space. (B) Pathology specimen demonstrating “red, beefy” appearance of resected intramedullary ependymoma.
Fig. 2Intraoperative view of resection cavity of cervical ependymoma. Note the pial traction stitches.
Summary of surgical resection series for ependymomas and astrocytomas illustrating the largest published series with at least 50 patients or greater
| Study | Pathology | Sample size | Recurrence rate | Morbidity | Extent of resection | Factors affecting outcome |
|---|---|---|---|---|---|---|
| Abdel-Wahab et al | Ependymoma; astrocytoma | 120; 57 | 32% within 22-mo mean follow-up (PFS at 5, 10, 15 y calculated at 70, 60, 35%); 58% within 21-mo mean follow-up (PFS at 5, 10, 15 y calculated at 42, 29, 15%) | Info incomplete for majority of patients | 63 GTR (52.5%); 57 STR or biopsy; 5 unknown (includes 6 other histology); 13 GTR (23%); 40 STR or biopsy | Tumor histology; extent of resection in ependymoma; radiation in astrocytoma but not ependymoma; age in astrocytoma |
| Boström et al | Ependymoma | 57 | PFS 89% at 5 y and 84% at 10 y | 7% had permanent drop in McCormick grade | 47 GTR (83%) | GTR; preoperative neurologic status |
| Garcés-Ambrossi et al | Ependymoma; astrocytoma | 51; 10 LG, 9 HG | 5-y PFS 82%, median time to progression 20 mo; median time to progression 6 mo | 33% acute decline in neurologic status; 30% acute decline; 55% acute decline; 41% of patients at baseline by 1 mo | 36 GTR (71%); 4 GTR (40%); 4 GTR (44%) | Intraoperative tumor plane present vs. absent; GTR in ependymoma; resolution of neurologic symptoms before discharge |
| Karikari et al | Ependymoma (includes 9 myxopapillary and 3 subependymoma); astrocytoma | 55; 17 LG; 4 HG (3 grade III, 1 grade IV) | 4 patients had recurrence; 10 patients had recurrence (5 grade I, 2 grade II, 1 grade IV) | 20% improved, 69% stable, 11% decline in neurologic function; 5% improved, 48% stable, 48% decline | 50 GTR (91%); 3 GTR (14.3%), all were grade 1 | Tumor histology; preoperative neurologic status; presence of plane of dissection; no association with location |
| Klekamp | Ependymoma; astrocytoma | 99; 76 | 5.1% recurrence at 10 y (0% GTR, 20.5% STR); 42.6% at 10 y (benign 28.8%, malignant 78.2%) (benign GTR or STR 6.3%; biopsy or partial resection 42.5%) | 27.3% permanent neurologic deficit; 18.4% permanent neurologic deficit | 85 GTR (86%); 7 STR; 7 partial/biopsy; 15 GTR (20%); 19 STR; 42 partial/biopsy | Tumor histology; tumor grade; preoperative neurologic status; spinal level; surgeon experience; extent of resection in ependymomas |
| Kucia et al | Ependymoma | 67 | Average time to recurrence 3.9 y | 23 (34%) had surgical complications | 55 GTR (82%) | Preoperative neurologic status; GTR |
| Lee et al | Ependymoma (IM and extramedullary included in study) | 59 (IM only) | 17% at 10 y (PFS 87% at 5 y, 80% at 10 y) | 45% postoperative decline; 50% of these improved at 1 mo | 52 GTR (88%); 11 STR; 1 partial/biopsy | Extent of resection; radiation and STR no benefit over GTR; preoperative neurologic status |
| Yang et al | Ependymoma | 85 | 1 case (1.2%) recurrence mean 69 mo follow-up; 3 cases (2.3%) recurrence mean 69 mo follow-up; 6 cases (100%) recurrence mean 69 mo follow-up | 73% improved, 25% stable, 1% decline in neurologic function; 66% improved, 20% stable, 10% decline; all patients died by mean 69-mo follow-up | 79 GTR (92.9%); 23 GTR (41.1%); 1 GTR (16.7%) | Tumor histology and grade |
Abbreviations: GTR, gross total resection; HG, high-grade histology (grade III or IV); IM, intramedullary; LG, low-grade histology (grade I or II); PFS, progression-free survival; STR, subtotal resection.
Note: This list is not comprehensive.
Fig. 3Treatment algorithm for IMSCTs. Abbreviations: GTR, gross total resection; IMSCT, intramedullary spinal cord tumor; MRI, magnetic resonance imaging; STR, subtotal resection.